Lorem ipsum dolor sit amet cons
ectetur adipiscing.
Recent Press Release
NovoMedix Presents New Preclinical Data on NMX2 at the 2022 American Heart Association (AHA) Scientific Sessions Meeting
SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- NovoMedix, LLC ("NovoMedix"), a biotechnology company developing novel, multi-pathway modulators for ...
AHA 2022 Meeting
The premier global event focusing on improving health by championing scientific discovery and practice-changing educational ...
NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TNBC
NovoMedix, LLC ("NovoMedix"), a biotechnology company creating novel, safe, and effective drugs to treat unmet ...
Lorem ipsum dolor
amet con sectet elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.